
0:00
39:08
In this episode we're delighted to welcome Professor Barbara Burtness from Yale School of Medicine to discuss the exciting results of the OrigAMI-4 trial and what they could mean for the future of head and neck cancer treatment.
We explore the emerging role of amivantamab. Barbara takes us through the rationale behind the study, its encouraging clinical results, and the potential implications for patients who have progressed despite immunotherapy and chemotherapy.
More episodes from "Deep Margin"



Don't miss an episode of “Deep Margin” and subscribe to it in the GetPodcast app.








